Fig. 7
Tumor-suppressing effects of MSC-Tandab against MM xenografts in NOD/SCID mice. (A) Schematic diagram of in vivo evaluation of MSC-Tandab. NOD/SCID mice were injected subcutaneously with H929 cells (5 × 106 per mouse) into the right flank. Following 13 days after xenografting (day 13), MSCs (1 × 106 per mouse) were injected via the tail vein. The Mice received an injection of PBMCs (1 × 107 per mouse) on day 16. The second treatment was administered on day 20. All mice were sacrificed on day 27. (B) The tumor weights of different groups were measured at the end of treatment. n = 5 tumors. (C) The tumor volume was calculated using the formula (width2 × length × 0.5). n = 5 tumors. (D) Serum cytokine levels on day 27. n = 5 tumors. (E) Changes in the body weight of H929 xenograft models during the treatment. n = 5 tumors. (F) Representative confocal microscopy images for the tumor tissues in each treatment group on the day 27. Green (anti-CD3) indicates T cells, red (TUNEL) indicates apoptosis in tumors, and blue (DAPI) indicates nuclei. The dashed boxes indicate areas of apoptosis, while the white arrows denote T cell infiltration. Scale bar = 50 μm. n = 5 tumors. (G) Histological analysis of organs from the xenograft model mice. On day 27, organs including the liver, spleen, and kidneys were dissected and fixed prior to hematoxylin and eosin (HE) staining. Scale bar = 100 μm. n = 5 tumors. ns, not significant, *P < 0.05, ***P < 0.001 compared with the corresponding MSC-EV + T group